English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Simcere Pharmaceutical Group Announces SFDA Approval to Manufacture and Market Palonosetron in China

Aug. 11, 2010

Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing and marketing of branded generic and proprietary pharmaceutical products in China, announced on August 12, 2010 that its subsidiary company Simcere Dongyuan Pharmaceutical Co., Ltd. has recently received SFDA new drug certification and registration approval to manufacture and market Palonosetron material and injections in China.
Palonosetron is a second generation 5-HT3 antagonist used for the prevention and control of acute chemotherapy-induced nausea and vomiting (CINV). According to industry analysis, 5-HT3 antagonists account for 90 percent of the CINV market in China.